Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Hoffmann-La Roche
Children's Oncology Group
University of Nebraska
Eli Lilly and Company
Jazz Pharmaceuticals
ITM Solucin GmbH
National Cancer Institute (NCI)
University of Southern California
National Institutes of Health Clinical Center (CC)
Children's Oncology Group
Medical College of Wisconsin
Institut Curie
BeiGene
National Cancer Institute (NCI)
Taproot Health
National Cancer Institute (NCI)
Catalysis SL
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
UNICANCER
Masonic Cancer Center, University of Minnesota
Y-mAbs Therapeutics
Children's Oncology Group
National Cancer Institute (NCI)
Eisai Inc.
Canadian Cancer Trials Group
Canadian Cancer Trials Group
City of Hope Medical Center
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Children's Oncology Group
CHA University
Rush University Medical Center
Radiation Therapy Oncology Group
M.D. Anderson Cancer Center
Rutgers, The State University of New Jersey
Case Comprehensive Cancer Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Radiation Therapy Oncology Group